Antiandrogens as Therapies for COVID-19: A Systematic Review

    January 2024 in “ Cancers ”
    Massimiliano Cani, Samantha Epistolio, Giulia Dazio … Ricardo Pereira Mestre
    Studysummary This systematic review found that antiandrogens do not appear to protect against SARS-CoV-2 infection or reduce COVID-19 severity, suggesting their use is not advisable for COVID-19 treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 13

    1. 5-Alpha Reductase Inhibitors Use in Prostatic Disease and Beyond Translational Andrology and Urology · 2023
    2. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial Cureus · 2021
    3. Impact of Androgen Deprivation Therapy on Mortality of Prostate Cancer Patients with COVID-19: A Propensity Score-Based Analysis Infectious Agents and Cancer · 2021
    4. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial Frontiers in Medicine · 2021
    5. The Antiandrogen Enzalutamide Downregulates TMPRSS2 and Reduces Cellular Entry of SARS-CoV-2 in Human Lung Cells Nature Communications · 2021
    6. Finasteride in Hospitalized Adult Males with COVID-19: A Risk Factor for Severity or an Adjunct Treatment - A Randomized Controlled Clinical Trial Medical journal of the Islamic Republic of Iran · 2021
    7. The Clinical Applications of Five-Alpha Reductase Inhibitors Canadian Journal of Urology · 2021
    8. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial Cureus · 2021
    9. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial Cureus · 2021
    10. Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men Journal of The European Academy of Dermatology and Venereology · 2021
    11. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men Cell Stem Cell · 2020
    12. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    13. A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity Journal of Cosmetic Dermatology · 2020

    Related research 2

    1. The Antiandrogens Dermatologic Clinics · 1993
    2. The Antiandrogens: When And How They Should Be Used PubMed · 1993